GSK-2636771

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H22F3N3O3
Molecular Weight	433.4236
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=NC2=C(C=C(C=C2C(O)=O)N3CCOCC3)N1CC4=CC=CC(=C4C)C(F)(F)F

InChI

InChIKey=XTKLTGBKIDQGQL-UHFFFAOYSA-N

InChI=1S/C22H22F3N3O3/c1-13-15(4-3-5-18(13)22(23,24)25)12-28-14(2)26-20-17(21(29)30)10-16(11-19(20)28)27-6-8-31-9-7-27/h3-5,10-11H,6-9,12H2,1-2H3,(H,29,30)

HIDE SMILES / InChI

Molecular Formula	C22H22F3N3O3
Molecular Weight	433.4236
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23674493 | http://adisinsight.springer.com/drugs/800035521
Curator's Comment: Description was created based on several sources, including http://www.selleckchem.com/products/gsk2636771.html

GSK-2636771 is a potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines. GSK-2636771 shows selectively inhibitory activity in PTEN null cell lines (human prostate adenocarcinoma PC-3 and breast cancer HCC70) with EC50 of 36 nM and 72 nM, respectively. GSK-2636771 significantly decreases cell viability in p110β-reliant PTEN-deficient PC3 prostate and BT549 and HCC70 breast cancer cell lines, and leads to a marked decrease of AKT phosphorylation only in the control prostate and breast cancer cell lines. On April 1 2016 GlaxoSmithKine completes a phase-I/II trial for Solid tumours (Late-stage disease) in USA, United Kingdom and South Korea (NCT01458067).

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
PI3-kinase p110-beta subunit 31 Target ID: CHEMBL3145 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25387153	Inhibitor 8297		0.089 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Advanced gastric adenocarcinoma 3 Sources: https://clinicaltrials.gov/ct2/show/NCT02615730 http://adisinsight.springer.com/drugs/800035521	Primary		Phase II 1132	Unknown Approved Use Unknown
Solid tumors 145 Sources: https://clinicaltrials.gov/ct2/show/NCT02465060 http://adisinsight.springer.com/drugs/800035521	Primary		Phase II 1132	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
15078 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28645941	400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered:	GSK-2636771 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
29530 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28645941	500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:	GSK-2636771 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
5493 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28645941	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	GSK-2636771 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7221 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28645941	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:	GSK-2636771 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
205014 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28645941	400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered:	GSK-2636771 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
485325 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28645941	500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:	GSK-2636771 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
161874 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28645941	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	GSK-2636771 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
190798 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28645941	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:	GSK-2636771 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
23.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28645941	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:		GSK-2636771 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
23 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28645941	500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered:		GSK-2636771 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY443026	https://www.001chemical.com/chem/search?q=DY443026
1PlusChem LLC	1P009CSR	https://www.1pchem.com/search?query=1P009CSR
AChemBlock	L14953	http://www.achemblock.com/catalogsearch/result/?q=L14953
AK Scientific	2447AH	https://aksci.com/item_detail.php?cat=2447AH
AK Scientific	SYN5712	https://aksci.com/item_detail.php?cat=SYN5712
AOBIOUS INC	AOB87319	http://aobious.com/aobious/search?search_query=AOB87319
Aceschem	ACF019886	https://www.aceschem.com/catalog/search.do?q=ACF019886
Angene	AGN-PC-0WADEM	http://www.angenechemical.com/productshow/AGN-PC-0WADEM.html
ApexBio Technology	B2186	https://www.apexbt.com/catalogsearch/result/?q=B2186
AstaTech	42562	http://astatechinc.com/CPSResult.php?CRNO=42562
Axon MedChem	1912	https://www.axonmedchem.com/product/1912
Capot Chemical	24810	https://www.capotchem.com/search.do?q=24810
Cayman Chemical	17380	http://www.caymanchem.com/app/template/Product.vm/catalog/17380
Chem Scene	CS-0747	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0747
ChemShuttle	104780	https://www.chemshuttle.com/catalogsearch/result/?q=104780
Debye Scientific	DA-33589	https://www.debyesci.com/index.php?id=product&ext[cno]=DA-33589
Excenen	EX-A434	http://www.excenen.com/searchresultlist.php?id=EX-A434
Hairui	HR33037	http://www.hairuichem.com/en/product/search.do?q=HR33037
KeyOrganics	AS-17013	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-17013
Matrix Scientific	145186	http://www.matrixscientific.com/145186.html
MedChem Express	HY-15245	https://www.medchemexpress.com/search.html?q=HY-15245&ft=&fa=&fp=
Molcore	MC443026	http://www.molcore.com/CatMC443026.html
Molnova	M11535	https://www.molnova.com/en/serch-list.html?keywords=M11535
MuseChem	I001433	https://www.musechem.com/product/I001433.html
Ryan Scientific	101-93961	https://ryansci.com/products?q=101-93961&list_q=&search_type=exact
Ryan Scientific	Fexinidazole	https://ryansci.com/products?q=Fexinidazole&list_q=&search_type=exact
Selleck Chemicals	S8002	http://www.selleckchem.com/search.html?searchDTO.searchParam=S8002
ShangHai Biochempartner	BCP000623	http://www.biochempartner.com/search_BCP000623
ShangHai Biochempartner	BCP05688	http://www.biochempartner.com/search_BCP05688
TargetMol	T2073	https://www.targetmol.com/search?keyword=T2073
eMolecules	44786261	https://orderbb.emolecules.com/search/#?query=44786261
eMolecules	44848372	https://orderbb.emolecules.com/search/#?query=44848372
eNovation Chemicals	D572819	https://www.enovationchem.com/Products.asp?SEARCHTEXT=D572819&searchbtn.x=0&searchbtn.y=0
mcule	MCULE-7659851063	https://mcule.com/MCULE-7659851063/

PubMed

Title	Date	PubMed
PI3K pathway dependencies in endometrioid endometrial cancer cell lines.	2013 Jul 1	23674493

Patents

Sample Use Guides

In Vivo Use Guide

Increasing dose levels of GSK-2636771 (300 mg or 400 mg once daily)

Route of Administration: Oral

In Vitro Use Guide

GSK-2636771 (1 uM) durably suppressed P-AKT levels in ZR75-1 and MDA-MB-415 cells

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:15:38 GMT 2023` Edited by `admin` on `Fri Dec 15 15:15:38 GMT 2023`
Record UNII	DW94IAT0LS
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

GSK-2636771

Common Name

English

GSK2636771

Code

English

GSK 2636771 [WHO-DD]

Common Name

English

2-METHYL-1-((2-METHYL-3-(TRIFLUOROMETHYL)PHENYL)METHYL)-6-(4-MORPHOLINYL)-1H-BENZIMIDAZOLE-4-CARBOXYLIC ACID

Systematic Name

English

2-METHYL-1-((2-METHYL-3-(TRIFLUOROMETHYL)PHENYL)METHYL)-6-MORPHOLINO-BENZIMIDAZOLE-4-CARBOXYLIC ACID

Systematic Name

English

Code System Code Type Description

DRUG BANK

DB11795